The value of 18 F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis

Assessment of early response to imatinib 800 mg after 400 mg progression by18F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors

(2015) Matías Chacón et al.   Future Oncology

PET Response Criteria for Solid Tumors Predict Survival at Three Months After Intra-Arterial Resin-Based 90Yttrium Radioembolization Therapy for Unresectable Intrahepatic Cholangiocarcinoma

(2014) Juan C. Camacho et al.   CLINICAL NUCLEAR MEDICINE

The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies

(2014) Tong Dai et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

(2014) Katherine Zukotynski et al.   CANCER IMAGING

QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

(2013) Penny F. Whiting   ANNALS OF INTERNAL MEDICINE

Gastrointestinal Stromal Tumors

(2013) Markku Miettinen et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review

(2012) Giorgio Treglia et al.   CLINICAL IMAGING

ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with 18F-FDG PET and Correlation with Genotype and GLUT4 Expression

(2012) A. D. Van den Abbeele et al.   JOURNAL OF NUCLEAR MEDICINE

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

(2011) Heikki Joensuu et al.   LANCET ONCOLOGY

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib

(2010) Joan Maurel et al.   CANCER

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Highlighting the Role of FDG PET Scan in Early Response Assessment of Gastrointestinal Stromal Tumor Treated With Imatinib Mesylate

(2009) Suman A. Abhyankar et al.   CLINICAL NUCLEAR MEDICINE

A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis

(2008) John C. McAuliffe et al.   ANNALS OF SURGICAL ONCOLOGY

Risk stratification of patients diagnosed with gastrointestinal stromal tumor

(2008) Heikki Joensuu   HUMAN PATHOLOGY

Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor

(2008) John O. Prior et al.   JOURNAL OF CLINICAL ONCOLOGY